Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:43 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 1,050 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Cell Transfer Clear all

Conditions: Colon Cancer Liver Metastasis, Colon Cancer, Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Liver Metastasis Colon Cancer, Colorectal Cancer
Interventions: Y90 TARE, PET/CT, PET/MRI; Radiation · Diagnostic Test
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Acute Myeloid Leukemia With Complex Karyotype, Myelodysplastic Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome, Recurrent Secondary Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Refractory Myelodysplastic Chronic Myelomonocytic Leukemia, Refractory Myelodysplastic Syndrome, Refractory Secondary Acute Myeloid Leukemia
Interventions: Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Echocardiography Test, Fludarabine Phosphate, Melphalan, Multigated Acquisition Scan, Palifermin, Peripheral Blood Stem Cell Transplantation, Questionnaire Administration, Sirolimus, Tacrolimus, Total Marrow and Lymphoid Irradiation; Procedure · Drug · Biological + 2 more
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Duarte, California

Conditions: Acute Myelogenous Leukemia, Myelodysplasia
Interventions: autologous tumor cells; Biological
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2006
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Major Depressive Disorder
Interventions: Transcranial Magnetic Stimulation; Device
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Advanced Cancers, Lymphoma
Interventions: Azacitidine, Vorinostat, Gemcitabine, Busulfan, Melphalan, Dexamethasone, Caphosol, Glutamine, Pyridoxine, Rituximab; Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 15 Years to 65 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Squamous Cell Carcinoma of Head and Neck, Squamous Cell Carcinoma of Head and Neck (SCCHN), HNSCC, Neoplasm Recurrence, Local, Recurrent Head and Neck Squamous Cell Carcinoma
Interventions: TMV Vaccine, Toripalimab-tpzi; Biological
Lead sponsor: Metaclipse Therapeutics Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Neuralgia
Interventions: Exosomes; Other
Lead sponsor: Neurological Associates of West Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Non Small Cell Lung Cancer
Interventions: Ipilimumab, Nivolumab, SBRT; Drug · Radiation
Lead sponsor: Brown University; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Hematopoietic Stem Cell Transplant
Interventions: PATH; Behavioral
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 3
States / cities: Tampa, Florida • Boston, Massachusetts • Durham, North Carolina

Conditions: Muscle Tear
Interventions: ADRCs prepared by investigational Celution Device, Placebo; Device · Biological
Lead sponsor: Cytori Therapeutics; Industry
Eligibility: 20 Years to 60 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 2
States / cities: Los Angeles, California • Houston, Texas

Conditions: Subarachnoid Hemorrhage, Vasospasm
Interventions: Red blood cell transfusion; Biological
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Sickle Cell Anemia, Pulmonary Hypertension
Interventions: Nitric Oxide, INO Pulse - NO Delivery System; Drug · Device
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2015
U.S. locations: 2
States / cities: Bethesda, Maryland

Conditions: Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma, Recurrent Primary Mediastinal Large B-Cell Lymphoma, Recurrent Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory Grade 3b Follicular Lymphoma, Refractory High Grade B-Cell Lymphoma, Refractory Primary Mediastinal Large B-Cell Lymphoma, Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions: Odronextamab, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Chimeric Antigen Receptor T-Cell Therapy, Computed Tomography, Leukapheresis, Lumbar Puncture, Positron Emission Tomography, Questionnaire Administration, Biopsy Procedure; Biological · Procedure · Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Myeloproliferative Disorders, Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia
Interventions: T-cell replete PBPC allograft, Methotrexate, Cyclosporine, G-CSF; Procedure · Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 2 Years to 80 Years
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Head and Neck Cancer, Cancer of the Pharynx, Cancer of the Larynx, Nose Neoplasms, Paranasal Sinus Neoplasms, Cancer of the Oral Cavity
Interventions: Cetuximab, Hydroxyurea, Fluorouracil, radiotherapy; Drug · Procedure
Lead sponsor: Johnny Kao; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Sickle Cell Disease, Stress, Pain
Interventions: Guided Relaxation video clip, Sickle Cell Disease Experience Discussion; Behavioral
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Melanoma (Skin)
Interventions: therapeutic autologous lymphocytes, Use of an artificial antigen presenting cell (aAPC) to generate CTL, GM-CSF, Irradiation of cutaneous tumor lesion; Biological · Genetic · Drug + 1 more
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Acute Myeloid Leukemia, Myeloproliferative Neoplasm, Myelodysplastic Syndromes
Interventions: VMAT-Based Total Marrow and Lymphoid Irradiation (TMLI), Fludarabine, Cyclophosphamide, Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT), Mycophenolate mofetil (MMF), Tacrolimus; Radiation · Drug · Biological
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Disc Degeneration
Interventions: MSC Treatment group 1 (low dose), MSC Treatment group 2 (high dose), Healthy Control (no treatment); Drug · Other
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Glioblastoma
Interventions: MRI-guided Laser Heat Ablation (MLA), Doxorubicin, Blood draw - dendritic cells, Dynamic Susceptibility Contrast Magnetic Resonance Imaging; Device · Drug · Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Colon Cancer
Interventions: PalloV-CC; Biological
Lead sponsor: George E. Peoples; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Severe Combined Immunodeficiency
Interventions: Gene-Transduced Autologous CD34+ Stem Cells; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Months to 20 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Breast Cancer, HER2-positive Breast Cancer, HER-2 Gene Amplification, HER2 Positive Breast Carcinoma, HER-2 Protein Overexpression, Breast Cancer, Male, Breast Cancer Female
Interventions: HER2 DC1 Vaccine; Biological
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Dystonia
Interventions: Activa PC Primary Cell Neurostimulator - (Model 37601), Activa RC Rechargeable Neurostimulator - (Model 37612), Activa SC Single Cell Neurostimulator (Models 37602/37603), DBS Lead - (Model 3387, DBS Extension - (Models 37085/6), Patient Programmer - (Model 37642), Test Stimulator - (Model 3625), N'Vision Clinician Programmer - (Model 8840), N'Vision Software Application Card - (Model 8870); Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 7 Years to 25 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: San Francisco, California

Search by objective public record fields.

Biopsy After Radioembolization to Identify Changes in Tumor Cells From the Radiation

Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplant in Older Patients With Refractory and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome

Study of Vaccination With Autologous Acute Myeloblastic Leukemia Cells in Patients With Advanced Myelodysplasia or Acute Myelogenous Leukemia

Spectral TMS (s-TMS)

Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma

TMV Vaccine Alone or With Toripalimab-tpzi for Recurrent Head and Neck Squamous Cell Carcinoma

The Use of Exosomes In Craniofacial Neuralgia

BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab

Positive Psychology Intervention for Hematopoietic Stem Cell Transplantation Survivors

Safety and Feasibility of ADRCs (Adipose Derived Regenerative Cells) in Patients With Grade II Hamstring Tears

Effect of Red Blood Cell Transfusion on Brain Metabolism in Patients With Subarachnoid Hemorrhage

Nitric Oxide and Transfusion Therapy for Sickle Cell Patients With Pulmonary Hypertension

Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T

Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow

Fluorouracil, Hydroxyurea, Cetuximab and Twice-daily Intensity Radiation Therapy for Advanced Head and Neck Cancer

The Feasibility of the PAINReportIt Guided Relaxation Intervention-INPATIENT

Adoptive Transfer of MART1/Melan-A CTL for Malignant Melanoma

Automated Total Marrow and Lymphoid Irradiation for Allogeneic Hematopoietic Cell Transplant

Mesenchymal Stem Cells for Lumbar Degenerative Disc Disease

MRI-Guided Laser Surgery and Doxorubicin Hydrochloride in Treating Patients With Recurrent Glioblastoma Multiforme

Trial of PalloV-CC in Colon Cancer

Stem Cell Gene Therapy to Treat X-Linked Severe Combined Immunodeficiency (XSCID)

Immune Response and Potential Booster for Patients Who Have Received HER2-pulsed DC1

Thalamic Deep Brain Stimulation for Secondary Dystonia in Children and Young Adults